GlassScriptPhysician profile
Dustin Deemer
NPI 1558549592
$1,747.21
in general payments reported to CMS, 2019-2025
21 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $1,053 · 2024: $72.26 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $304.20 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $285.84 | 2023-2025 | |
| Abbvie INC. | $266.39 | 2022-2024 | |
| Dexcom, INC. | $227.33 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $141.59 | 2023 | Korlym |
| Abbott Laboratories | $73.10 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $70.82 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $69.79 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $52.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $44.25 | 2023-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.65 | 2025 | Caplyta |
| Halozyme INC | $23.44 | 2023 | |
| Cequr Corporation | $22.97 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.26 | 2023 | Jardiance, Synjardy |
| Beta Bionics, INC. | $21.42 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $20.21 | 2023 | Afrezza |
| Axsome Therapeutics, INC. | $20.00 | 2025 | Symbravo |
| Antares Pharma, INC. | $15.43 | 2025 | Xyosted |
| Amarin Pharma, INC. | $14.89 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.20 | 2022 | |
| Merck Sharp & Dohme LLC | $12.95 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Deemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.